

#3



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/826,245	04/04/2001	Thyge Borup Hjorth	6184.200-US

CONFIRMATION NO. 2682

FORMALITIES LETTER



OC00000006092482

Nova Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401

Date Mailed: 05/18/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**

A copy of this notice MUST be returned with the reply.

H.T

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

07/11/2001 HNDOR1 00000079 141447 09826245

01 FC:105

130.00 CH



Attorney Docket No.: 6184.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hjorth, et al.

Serial No.: 09/826,245

Group Art Unit: 1614

Filed: April 4, 2001

Examiner: To be assigned

For: New Pharmaceutical Composition and The Process for Its Preparation

RESPONSE TO NOTICE TO FILE MISSING PARTS

Commissioner for Patents
Washington, DC 20231


Sir:

In response to the Notice to File Missing Parts dated May 18, 2001 (a copy thereof is attached hereto), Applicants submit the Combined Declaration and Power of Attorney signed and dated by Applicants for the above-captioned application.

Please charge the required fee, estimated to be \$130.00, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: 5 July 2001


Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6184.200-US

PATENT

Section #3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hjorth, et al.

Serial No.: 09/826,245

Group Art Unit: 1614

Filed: April 4, 2001

Examiner: To be assigned

For: New Pharmaceutical Composition and The Process for Its Preparation

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Notice to File Missing Parts (in duplicate)
3. Copy of Notice to File Missing Parts
4. Executed Combined Declaration and Power of Attorney


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on 5 July 2001.

Sylvia Gonzalez

(name of person mailing paper)



(signature of person mailing paper)